Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Other financing activities (2018)

Historic Other financing activities for Denali Therapeutics (DNLI) over the last 1 years, with Q1 2018 value amounting to $1.3 million.

  • Denali Therapeutics' Other financing activities changed N/A to $1.3 million in Q1 2018 from the same period last year, while for Dec 2018 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2018, which is N/A changed from last year.
  • Per Denali Therapeutics' latest filing, its Other financing activities stood at $1.3 million for Q1 2018.
  • Denali Therapeutics' Other financing activities' 5-year high stood at $1.3 million during Q1 2018, with a 5-year trough of $1.3 million in Q1 2018.